BIIB vs ZION · P/E 21, rev $9.89B vs P/E 11, rev $354.0M
Biogen Inc (BIIB) versus Zions Bancorporation (ZION) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Zions Bancorporation (ZION) is a banks - regional company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported ZION revenue for 2026-06-30 was $354.0M. Net income was $686.0M. ZION currently screens at market cap $8.19B and trailing P/E 10.8.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. ZION currently screens at market cap $8.19B and trailing P/E 10.8.
Not investment advice. Open the BIIB and ZION stock pages for the full models.
Not investment advice.